Premium
CC chemokine receptor 6 expression predicts poor prognosis in hepatocellular carcinoma
Author(s) -
Liu Feng,
Lv Hong,
Jia Xinyong,
Liu Guoming,
Li Tao,
Xu Zongzhen,
Li Jie
Publication year - 2014
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23598
Subject(s) - c c chemokine receptor type 6 , medicine , immunohistochemistry , hepatocellular carcinoma , chemokine receptor , western blot , pathology , carcinogenesis , cancer research , oncology , chemokine , receptor , cancer , biology , biochemistry , gene
Background Recent studies have demonstrated that the CC chemokine receptor 6 (CCR6) may be involved in tumorigenesis and tumor progression of various human malignancies. The aim of this study was to investigate the clinical significance and prognostic value of CCR6 expression in human hepatocellular carcinoma (HCC). Methods CCR6 protein levels were evaluated by Western blot in samples from 25 HCC and matched adjacent noncancerous liver tissues. CCR6 protein expression levels were also examined by immunohistochemistry in association with clinicopathologic features and prognosis in 212 HCC patients. The effects of CCR6 on HCC cell proliferation and invasion were examined in vitro. Results Western blot analysis showed significantly higher CCR6 protein in HCC than that in matched adjacent noncancerous liver tissues. By immunohistochemistry, CCR6 expression correlated with multicentricity ( P = 0.014) and vascular invasion ( P = 0.009). Importantly, CCR6 expression was an independent prognostic factor for the overall survival of HCC patients [hazard ratio = 3.07, 95% confidence interval (CI) = 1.94–4.76, P = 0.013]. In vitro data revealed that CCR6 promoting HCC cell proliferation through regulating p21, p27, and cyclin D1. Conclusions CCR6 could be used as a molecular marker to predict prognosis for HCC. J. Surg. Oncol. 2014; 110:151–155 . © 2014 Wiley Periodicals, Inc.